SCHEMBL770024

SCHEMBL770024

CCOC(=O)CN(CCc1ccc(O)cc1)C(=O)CCCC(=O)N1CCCC2CCCC=C21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 3/20 0.35
FAAH O00519 1/20 0.35
NAAA Q02083 1/20 0.35
ALDH1A1 P00352 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
ME2 P23368 1/20 0.33
ME1 P48163 1/20 0.33
ME3 Q16798 1/20 0.33
ALOX5 P09917 1/20 0.33
NPC1 O15118 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
PDK1 Q15118 1/20 0.31
PDK2 Q15119 1/20 0.31
PDK3 Q15120 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770840 0.93 ALDH1A1 (0.37) HRH3NAAAALDH1A1NPC1CYP3A4
SCHEMBL770267 0.93 ALOX5 (0.38) HRH3ALDH1A1ALOX5NPC1CYP3A4
SCHEMBL770669 0.90 KCNH2 (0.38) HRH3ALDH1A1L3MBTL1LMNA
SCHEMBL770279 0.88 ALDH1A1 (0.41) FAAHALDH1A1L3MBTL1ALOX5NPC1
SCHEMBL772068 0.81 SMN1; SMN2 (0.46) NAAAALDH1A1NPC1CYP3A4CYP2D6
SCHEMBL772447 0.80 ALDH1A1 (0.41) FAAHALDH1A1L3MBTL1ALOX5NPC1
SCHEMBL770041 0.80 RAB9A (0.42) HRH3ALDH1A1L3MBTL1NPC1CYP3A4
SCHEMBL770023 0.79 NPC1 (0.40) HRH3FAAHNAAAALDH1A1L3MBTL1
SCHEMBL771753 0.79 KMT2A (0.44) ALDH1A1L3MBTL1NPC1CYP2D6CYP2C9
SCHEMBL771071 0.79 TPSAB1 (0.38) ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HRH3 1687/4885FAAH 184/4885NAAA 3025/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HRH3 1698/4885FAAH 187/4885NAAA 3067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.